ProCE Banner Activity

ORCHARD: Phase II Study of Osimertinib + Datopotamab Deruxtecan in Advanced EGFRm NSCLC After 1L Osimertinib

Conference Coverage
Slideset

Analysis of module 10 from the phase II ORCHARD trial suggested favorable ORR and mPFS outcomes with osimertinib + Dato-DXd for patients with advanced EGFRm NSCLC who had progressed after 1L osimertinib.

Released: April 10, 2025

Expiration: October 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc